Emerging in the landscape of excess body fat treatment, retatrutide presents a distinct method. Beyond many existing medications, retatrutide operates as a double agonist, simultaneously affecting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) receptors. The simultaneous activation promotes various benefici